CRGN-F
CuraGen Contact:
Glenn Schulman, Pharm.D.
Director of Investor Relations
(888) 436-6642
CURAGEN CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
(unaudited) (unaudited)
Collaboration revenue $22 - $66 $2,284
Operating expenses:
Research and development 8,074 10,692 30,480 33,139
General and administrative 2,568 3,556 9,631 10,287
Restructuring and other charges 1,058 - 8,537 -
Total operating expenses 11,700 14,248 48,648 43,426
Loss from operations (11,678) (14,248) (48,582) (41,142)
Interest income 1,861 1,742 4,060 5,452
Interest expense (1,273) (2,334) (4,172) (7,019)
Gain on extinguishment of debt 169 - 169 -
Gain on sale of long-term
marketable securities 973 - 973 -
Loss from continuing operations
before income tax benefit (9,948) (14,840) (47,552) (42,709)
Income tax benefit 50 52 160 161
Loss from continuing operations (9,898) (14,788) (47,392) (42,548)
Discontinued operations:
Loss from discontinued
operations - (1,
'/>"/>
| SOURCE CuraGen Corporation Copyright©2007 PR Newswire. All rights reserved |